Zacks Investment Research lowered shares of Pharming Group (OTCMKTS:PHGUF) from a hold rating to a sell rating in a report issued on Wednesday.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Several other research analysts have also commented on the stock. HC Wainwright restated a buy rating on shares of Pharming Group in a report on Thursday, October 26th. ValuEngine lowered shares of Pharming Group from a hold rating to a sell rating in a research note on Friday, December 1st.
Pharming Group (OTCMKTS PHGUF) opened at $1.50 on Wednesday. Pharming Group has a 1-year low of $0.30 and a 1-year high of $1.58. The company has a quick ratio of 1.27, a current ratio of 1.77 and a debt-to-equity ratio of 11.72.
ILLEGAL ACTIVITY NOTICE: “Pharming Group (PHGUF) Stock Rating Lowered by Zacks Investment Research” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/14/pharming-group-phguf-stock-rating-lowered-by-zacks-investment-research.html.
Pharming Group Company Profile
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.